Página 1 desde 19 resultados
The present invention relates to a series of substituted heteroaromatic compounds, methods for their preparation, pharmaceutical compositions containing them and their use in medicine. In particular, the invention relates to bioisosteres of quinoline and quinazoline derivatives which exhibit protein
REFERENCE TO SEQUENCE LISTING
This application contains a Sequence Listing submitted as an electronic text file named " Sequence_Listing.sub.--2848-95-PUS_ST25" having a size in bytes of 183 KB, and created on Sep. 30, 2010. The information contained in this electronic file is hereby incorporated by
1. FIELD OF THE INVENTION
The present invention relates to synthetic substituted heterocyclic compounds and pharmaceutical compositions containing the same that are capable of inhibiting or antagonizing a family of receptor tyrosine kinases, Tropomysosin Related Kinases (Trk), in particular the
1. FIELD OF THE INVENTION
The present invention relates to synthetic substituted heterocyclic compounds and pharmaceutical compositions containing the same that are capable of inhibiting or antagonizing a family of receptor tyrosine kinases, Tropomysosin Related Kinases (Trk), in particular the
1. FIELD OF THE INVENTION
The present invention relates to synthetic substituted heterocyclic compounds and pharmaceutical compositions containing the same that are capable of inhibiting or antagonizing a family of receptor tyrosine kinases, Tropomysosin Related Kinases (Trk), in particular the
1. FIELD OF THE INVENTION
The present invention relates to synthetic substituted heterocyclic compounds and pharmaceutical compositions containing the same that are capable of inhibiting or antagonizing a family of receptor tyrosine kinases, Tropomysosin Related Kinases (Trk), in particular the
1. FIELD OF THE DISCLOSURE
The present disclosure relates to synthetic substituted heterocyclic compounds and pharmaceutical compositions containing the same that are capable of inhibiting or antagonizing protein kinase activities. The disclosure further concerns the use of such compounds in the
1. FIELD OF THE DISCLOSURE
The present disclosure relates to synthetic substituted heterocyclic compounds and pharmaceutical compositions containing the same that are capable of inhibiting or antagonizing protein kinase activities. The disclosure further concerns the use of such compounds in the
REFERENCE TO SEQUENCE LISTING
This application contains a Sequence Listing submitted as an electronic text file named "Sequence_Listing.txt", having a size in bytes of 183 kb, and created on Sep. 30, 2010. The information contained in this electronic file is hereby incorporated by reference in its
BACKGROUND OF THE INVENTION
The present invention is related to oxindole derivatives, compositions containing the same, and methods of use and manufacture of the same. Such compounds generally are useful pharmacologically as agents in those disease states alleviated by the alteration of mitogen
BACKGROUND OF THE INVENTION
The present invention is related to oxindole derivatives, compositions containing the same, and methods of use and manufacture of the same. Such compounds generally are useful pharmacologically as agents in those disease states alleviated by the alteration of mitogen
BACKGROUND
The present invention is directed to glycosulfopeptides and methods of their use in treating inflammation and disorders related to leukocyte rolling mediated by P-selectin binding.
Inflammation is the reaction of vascularized tissue to local injury. This injury can have a variety of
BACKGROUND OF THE INVENTION
Arteriosclerosis is a class of diseases characterized by the thickening and hardening of the arterial walls of blood vessels. Although all blood vessels are susceptible to this serious degenerative condition, the aorta and the coronary arteries serving the heart are most
BACKGROUND OF THE INVENTION
Arteriosclerosis is a class of diseases characterized by the thickening and hardening of the arterial walls of blood vessels. Although all blood vessels are susceptible to this serious degenerative condition, the aorta and the coronary arteries serving the heart are most
FIELD OF THE INVENTION
This invention relates to genetically engineered endothelial cells and, in particular, to genetically engineered endothelial cells which exhibit enhanced migration and enhanced plasminogen activator activity.
BACKGROUND OF THE INVENTION
Endothelial cells are specialized cells